An observational study in Breast Cancer, sponsored by GBG Forschungs GmbH. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by GBG Forschungs GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.
Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 32nd largest by planned enrollment of the 97 observational ones that give a count, is one of 45 that started in 2022, is one of 97 observational ones, reaches primary completion later than 260 of the 284 other live ones, and was the 712th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Sites in Spain
Ages 18+
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in Spain, United States, Belgium and 5 more countries
Ages 18+
Kenko Imalytics S.L. · Sites in Spain
Ages 18+ · Women only
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
905 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 327 · Phase 3 224 · Phase 4 13
First in 1996; this study’s year is marked. 45 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 151 across the 805 interventional studies, 200 across the 97 observational. Of the 576 that completed or were terminated, 291 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
533 of 905 have an industry lead sponsor. The 10 most frequent:
GBG Forschungs GmbH is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
GBG Forschungs GmbH has 7 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
78 of the studies in Breast Neoplasms with a site in Spain that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
Add all 78 to your calendar (.ics) → With an account.
Among the 905 studies in Breast Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ETERNITY study is an international, multicenter, observational study that aims to follow up patients who have participated in a GBG trial for early breast cancer, even after the study has officially ended, in order to collect long-term data on survival, late or delayed adverse events, in addition to information related to pregnancy, fertility and other parameters impacting quality of life.
This is a prospective and retrospective, international, multicenter, non-interventional, observational study for collection of long-term safety and efficacy parameters of former GBG study participants of prospective clinical trials on early breast cancer.
Patients with prospective data collection will be informed about the registry by the treating physician at the study site. After written informed consent (which may already be included in the main and/or biomaterial informed consent form of the respective clinical study) for data and biomaterial collection, the registration form will be filled out completely within the GBG electronic data capture system (MEDCODES®). Inclusion and registration can take place after informed consent of the patient. However, documentation of follow-up should start after the regular end of study or with the start of the follow-up period, as defined in the respective study protocol.
A correlation of the follow-up registry database with the respective study databases is possible via the patient identification number of the participant. Consequently, the long-term effects of the study therapy can be calculated per therapy group, and the effectiveness can be correlated with possible late-onset toxicities.
Post-study long-term outcome follow-up will be assessed according to local/national guidelines for standard follow-up examinations and post-treatment surveillance. Data should be documented at least once a year in the registry.
Relapse and safety assessment will be performed, and survival status will be collected in all registered patients. Here, the investigator may conduct evaluations or assessments within regular follow-up visits. However, telephone contact or contact in writing with the patient or treating physician or relatives in case of death is also acceptable. Imaging tests (e.g., mammography and/or staging workup) are recommended according to local/national guidelines for follow-up and in case of symptoms suspicious for locoregional or distant relapse.
Information to be collected include:
In case of disease recurrence, it is recommended to confirm diagnosis by histological examination. If performed, an FFPE tumor tissue block from the metastatic lesion should be provided to GBG.
It is allowed and recommended to register patients in parallel in the GBG self-reporting registry (available only in German) that will allow follow-up and long-term efficacy evaluations beyond the end of the respective study by the patients themselves.
STATISTICS
This is an observational study for collection of long-term safety and efficacy parameters of former GBG study participants. As long-term outcomes and late-onset toxicities are also secondary objectives in all prospective clinical studies of the GBG, statistical methods will adhere as much as possible to methods described in the respective clinical trial protocols.
For the analysis, data from the corresponding clinical trials (e.g., baseline characteristics, short-time efficacy, and toxicity parameters, already collected follow-up data, etc.) will be merged with the registry data.
DATA HANDLING, MANAGEMENT AND QUALITY ASSURANCE
The GBG EDC system MEDCODES® will be maintained by GBG Forschungs GmbH for all study sites.
Data management, which comprises CRF design, database and application hosting, data entry, and data validation, will be performed by GBG Forschungs GmbH for all study sites. GBG Forschungs GmbH will provide the investigator site with the web base EDC system MEDCODES® that is validated and conforms to 21 CFR Part 11 requirements. Investigator site staff will not be given access to MEDCODES® until they have been trained on the EDC system.
Visual and computerized methods of data validation are applied in order to ensure accurate, consistent, and reliable data for the subsequent analyses.
All communication between MedCODES® and the clients is securely encrypted (Secure HTTP).
In order to protect patient confidentiality, each participating patient is assigned a unique GBG patient identification number. Instead of the true patient identity, the pseudonym is used in all communication between the trial site and the GBG Forschungs GmbH. A correlation of the follow-up registry database with the respective study databases is possible via the patient identification number of the participant.
Every user is provided with a unique username and a unique password. Every user is assigned to a user group which represents their role in the CRF workflow. Access control is based on user name, group. Therefore, users can only access those datasets necessary for them to fulfill their role in the CRF workflow ("need to know basis").
Patients who participated and received treatment as part of a GBG clinical trial for early breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Disease-free survival (DFS)
Time period between randomization and first event (ipsi- or contralateral (non-) in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast))
Time frame: 10 years
Invasive disease-free survival (iDFS)
Time period between randomization and first event (ipsi- or contralateral invasive in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast))
Time frame: 10 years
Distant disease-free survival (DDFS)
Time period between randomization and diagnosis of any distant recurrence of disease, any second primary invasive cancer (non-breast) or death due to any cause, whichever occurs first
Time frame: 10 years
Locoregional recurrence-free survival (LRRFS)
Time period between randomization and diagnosis of any loco-regional (ipsilateral breast (invasive or DCIS), local/regional lymph nodes) recurrence of disease, any invasive contralateral breast cancer or death due to any cause, whichever occurs first
Time frame: 10 years
Overall survival (OS)
Time period between randomization and death of any cause
Time frame: 10 years
Other primary outcome measures
Other study-specific long-term survival endpoints may be defined in the respective study protocol or statistical analysis plan (SAP)
Time frame: 10 years
Long-term toxicity
Frequency and severity of long-term toxicity associated with study treatment are graded by the current NCI Common Terminology Criteria for Adverse Events version (NCI-CTCAE) or according to the respective study protocol or statistical analysis plan (SAP)
Time frame: 10 years
Anti-cancer therapies
Anti-cancer therapies including anti-hormonal therapy in hormone receptor positive (HR+) breast cancer after study participation are analyzed descriptively
Time frame: 10 years
Pregnancies
Pregnancies after study participation and their outcome are analyzed descriptively.
Time frame: 10 years
Impact of study treatment on Quality of Life (QoL)
In this registry, two questions on content on quality of life and degree of bother by side-effects are used
Time frame: 10 years
Explorative translational research endpoints
Correlation of explorative biomarkers with survival and toxicity endpoints. Details are defined in the corresponding SAP
Time frame: 10 years
Started Oct 2022 (actual). Primary completion is estimated for May 2030, 91 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 91 months is above that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GBG Forschungs GmbH